CClinicalTrials.gg
CompletedNCT02241954VEPTRUpdated May 12, 2020

Vertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome

An observational study in Thoracic Insufficiency Syndrome (TIS), sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2020-05-12.

Sponsored by Vanderbilt University Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7
Ages
6 Months to 17 Years
Sex
All
01

Study summary

The hypothesis of the study is that individuals with poor pulmonary function secondary to TIS will benefit from expansion thoracoplasty. The investigators specific aims are to:

  1. Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation
  2. Offer expansion thoracoplasty therapy to TIS patients with

    1. poor pulmonary function at enrollment
    2. progressive decline in pulmonary function
    3. progressive chest wall and/or spinal deformity
    4. lack of appropriate increase in thoracic volume during growth
  3. Document efficacy of expansion thoracoplasty for TIS patients
Read the detailed description

Study procedures

  1. Patient Identification \& Enrollment Patients meeting the inclusion criteria will be invited to enroll in the study as described above.
  2. Serial clinical observation

    Patients will be followed over time for progression of thoracic insufficiency indicators:

    • Worsening respiratory status oFrequent respiratory infections oElevated resting respiratory rate oEase of fatigability oHypoxia and hypercapnia oMarionette sign (trunk and shoulder elevation and depression with respiration)
    • Primary diaphragmatic breathing (loss of chest wall mobility)
    • Progressive scoliosis
    • Failure of thoracic dimensions to increase with growth

    Patients with progressive thoracic insufficiency will be offered surgical intervention with expansion thoracoplasty utilizing the VEPTR device.

    Studies which are standard of care for TIS will be utilized to assess patients. Routine standard of care studies will be obtained:

    1. MRI of the spine will be obtained at presentation.
    2. Chest CT scan (every 2 years, or less frequently if clinically indicated)
    3. AP/Lat spine xrays (to include the chest wall)

    <!-- -->

    1. Will be obtained every 6 months - 12 months
    2. If a patient has a VEPTR implantation, the typical schedule of radiographs would include immediate postoperative xrays (the day of surgery and/or early postoperative period) and at 6 weeks, 12 weeks, and 6 months postoperative.
    3. VEPTR lengthening will typically take place every 6 months after the initial VEPTR implantation.

    i.Xrays will be obtained every 6 months in association with the VEPTR lengthening.

    ii.Once VEPTR lengthening is no longer clinically indicated, the patients will be followed with xrays every 6-24 months until skeletal maturity.

    d.Pulmonary function tests (spirometry) will be obtained every 6-12 months in children who are old enough to participate (typically > age 4 years).

    e.Arterial and/or capillary blood gases

    a.Blood gases will be obtained every 6-12 months if clinically indicated and perioperatively for VEPTR implantation / lengthening.

    f.Routine vital signs including resting pulse oximetry (SaO2)

    a.Will be assessed at clinic visits and perioperatively g.All of the above mentioned studies will be obtained more or less frequently as clinically indicated.

  3. Expansion thoracoplasty with VEPTR implantation and subsequent lengthening with the VEPTR will be performed following informed consent. The surgical technique will be as described by Campbell.3 The VEPTR device will be lengthened at 6 to 12 month intervals until thoracic and spinal deformities have stabilized radiographically.
02

Conditions studied

  • Thoracic Insufficiency Syndrome (TIS)

Browse trials for

03

In context

Syndrome

9,217 studies on the registry are indexed under Syndrome; 1,031 are open to participants now.

This study's enrollment of 7 is below the median of 102 across 2,209 observational studies indexed under Syndrome.

Browse Syndrome studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients, age range from 6 months to 17 years with thoracic insufficiency syndrome (TIS). Categories of TIS include:

  1. Flail chest syndrome
  2. Constrictive chest wall syndrome (rib fusions and scoliosis)
  3. Hypoplastic thorax syndrome (Jeune's syndrome, achondroplasia, Jarcho-levin syndrome, Ellis van Creveld syndrome)
  4. Progressive scoliosis/kyphosis of congenital, neurogenic, or idiopathic origin without rib anomaly
  5. Early onset scoliosis without rib anomaly at high risk for progression

Inclusion criteria

  • Pediatric patients, age range from 6 months - 17 years with thoracic insufficiency syndrome (TIS) will be considered for inclusion. Categories of TIS include:

    1. Flail chest syndrome
    2. Constrictive chest wall syndrome (rib fusions and scoliosis)
    3. Hypoplastic thorax syndrome (Jeune's syndrome, achondroplasia, Jarcho-levin syndrome, Ellis van Creveld syndrome)
    4. Progressive scoliosis/kyphosis of congenital, neurogenic, or idiopathic origin without rib anomaly
    5. Early onset scoliosis without rib anomaly at high risk for progression

Exclusion criteria

Exclusion Criteria:

  • Failure to meet inclusion criteria.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7 participants (actual)
Patient registry
No

Groups and cohorts

  • Expansion Thoracoplasty

    The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.

    Device: Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)

Interventions

  • DeviceSynthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)
06

What researchers measure

Primary outcomes

  1. Pulmonary function and thoracic volume of TIS patients

    1)Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation postoperatively (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)

    Time frame: Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)

  2. ffer expansion thoracoplasty therapy to TIS patients meeting certain criteria (provided in description below)

    Offer expansion thoracoplasty therapy to TIS patients with * poor pulmonary function at enrollment * progressive decline in pulmonary function * progressive chest wall and/or spinal deformity * lack of appropriate increase in thoracic volume during growth

    Time frame: Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)

  3. Document efficacy of expansion thoracoplasty for TIS patients

    Time frame: Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)

07

Study locations

1 site
  • Monroe Carell Jr. Children's Hospital at Vanderbilt
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02241954
Lead sponsor
Vanderbilt University Medical Center
Responsible party
Jeffrey Martus (Assistant Professor of Orthopaedics, Vanderbilt University Medical Center) — Principal investigator
First posted
Sep 16, 2014
Start date
Nov 11, 2010
Primary completion
Mar 25, 2018
Completion
Feb 28, 2020
Last update
May 12, 2020

Study contacts

Jeffrey Martus, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion